UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 946

Sortiert nach

ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients

Supportive care in cancer, 2019-01, Vol.27 (1), p.87-95

2019

Volltextzugriff (PDF)

Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

International journal of clinical oncology, 2021-01, Vol.26 (1), p.1-17

2021

Volltextzugriff (PDF)

A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics

Cancer chemotherapy and pharmacology, 2017-09, Vol.80 (3), p.441-449

Badowski, Melissa E.

2017

Volltextzugriff (PDF)

CINV: still troubling patients after all these years

Supportive care in cancer, 2018-03, Vol.26 (Suppl 1), p.5-9

Aapro, Matti

2018

Volltextzugriff (PDF)

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients

Supportive care in cancer, 2024-05, Vol.32 (5), p.280-280, Article 280

2024

Volltextzugriff (PDF)

Chemotherapy: how to reduce its adverse effects while maintaining the potency?

Medical oncology (Northwood, London, England), 2023-02, Vol.40 (3), p.88-88, Article 88

2023

Volltextzugriff (PDF)

2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children

Supportive care in cancer, 2017, Vol.25 (1), p.323-331

2017

Volltextzugriff (PDF)

Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?

European journal of clinical pharmacology, 2022-06, Vol.78 (6), p.1029-1038

2022

Volltextzugriff (PDF)

Discovering different acupoint combinations of manual or electro-acupuncture to treat chemotherapy-induced nausea and vomiting based on the complex networks analysis

Supportive care in cancer, 2024-01, Vol.32 (1), p.78-78, Article 78

2024

Volltextzugriff (PDF)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France

Digestive diseases and sciences, 2016-10, Vol.61 (10), p.3072-3083

2016

Volltextzugriff (PDF)

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

Supportive care in cancer, 2024-01, Vol.32 (1), p.47-47, Article 47

2024

Volltextzugriff (PDF)

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Supportive care in cancer, 2024-01, Vol.32 (1), p.36-36, Article 36

2024

Volltextzugriff (PDF)

Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine—a case series

Supportive care in cancer, 2024-05, Vol.32 (5), p.290-290, Article 290

2024

Volltextzugriff (PDF)

The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study

Supportive care in cancer, 2024-05, Vol.32 (5), p.291-291, Article 291

2024

Volltextzugriff (PDF)

Nomogram for predicting opioid-induced nausea and vomiting for cancer pain patients

Supportive care in cancer, 2023-12, Vol.31 (11), p.663-663, Article 663

2023

Volltextzugriff (PDF)

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation

Supportive care in cancer, 2024-01, Vol.32 (1), p.53-53, Article 53

2024

Volltextzugriff (PDF)

Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis

Supportive care in cancer, 2020-05, Vol.28 (5), p.2095-2103

2020

Volltextzugriff (PDF)

Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea

Supportive care in cancer, 2024-03, Vol.32 (3), p.190-190, Article 190

2024

Volltextzugriff (PDF)

Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses

Supportive care in cancer, 2018-02, Vol.26 (2), p.557-564

2018

Volltextzugriff (PDF)

Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study

Supportive care in cancer, 2023-12, Vol.31 (11), p.657-657, Article 657

2023

Volltextzugriff (PDF)

Revisiting the physiology of nausea and vomiting—challenging the paradigm

Supportive care in cancer, 2020, Vol.28 (1), p.13-21

Wickham, Rita J.

2020

Volltextzugriff (PDF)

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Supportive care in cancer, 2017-01, Vol.25 (1), p.303-308

2017

Volltextzugriff (PDF)

2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

Supportive care in cancer, 2024-01, Vol.32 (1), p.45-45, Article 45

2024

Volltextzugriff (PDF)

Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis

Supportive care in cancer, 2024-01, Vol.32 (1), p.58-58, Article 58

2024

Volltextzugriff (PDF)

Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis

Supportive care in cancer, 2022-11, Vol.30 (11), p.8855-8869

2022

Volltextzugriff (PDF)

1 – 25 von 946

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(915)
Mit Volltextzugriff
(916)

Publikationsform

Artikel
(946)

Sprache

Englisch
(912)
Japanisch
(128)
Deutsch
(34)
Italienisch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(927)
Life Sciences & Biomedicine
(844)
Science & Technology
(844)
Nausea - Chemically Induced
(823)
Female
(685)
Oncology
(658)
Vomiting - Chemically Induced
(602)
Middle Aged
(583)
Male
(573)
Medicine
(515)
Medicine & Public Health
(514)
Adult
(501)
Chemotherapy
(462)
Nausea
(462)
Aged
(452)
Antineoplastic Agents - Adverse Effects
(365)
Health Care Sciences & Services
(335)
Rehabilitation
(333)
Vomiting
(311)
Antiemetics - Therapeutic Use
(307)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients

Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics

CINV: still troubling patients after all these years

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients

Chemotherapy: how to reduce its adverse effects while maintaining the potency?

2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children

Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?

Discovering different acupoint combinations of manual or electro-acupuncture to treat chemotherapy-induced nausea and vomiting based on the complex networks analysis

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine—a case series

The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study

Nomogram for predicting opioid-induced nausea and vomiting for cancer pain patients

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation

Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis

Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea

Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses

Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study

Revisiting the physiology of nausea and vomiting—challenging the paradigm

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis

Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis

Aktive Filter

Suchergebnisse filtern